MDXG (MiMedx Group, Inc.) Future Price to Earnings

The valuation of MiMedx Group, Inc. (MDXG) based on forward P/E demonstrates price dynamics, where the current parameter stands at 106.40. The business relies on domestic US plants, which eliminates external political risks. Exclusive patents for wound healing and healthcare sector support create significant barriers to entry for newcomers. A high entry threshold is also driven by strict FDA oversight and the complexity of clinical trials for biologics.

MDXG - MiMedx Group Inc Projected Price to Earnings Ratio over the range 07/04/2022 - 11/14/2026

Analytical breakdowns for MiMedx Group, Inc.

- current price and projected stock value:

Stock Quotes MiMedx Group|MDXG - Fair Value Consensus

- business market valuation indicators:

Market Value MiMedx|MDXG - Real Price to Acquire Entire Company

- balance sheet equity data:

Book Value per Share MiMedx|MDXG - Total Stockholders' Equity|Market Cap to Net Assets Ratio mimedx.com|MDXG - Aggregate Business Assets

- issuer credit burden and liquidity indicators:

- earnings and market ratios statistics:

MDXG - Net Financial Result|Expected Profit MiMedx Group, Inc.|MDXG - Business Payback Period|Future Price to Earnings mimedx.com|MDXG - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MiMedx|MDXG - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) MiMedx|MDXG - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months mimedx.com|MDXG - Net earnings per share growth this year|Earnings growth forecast for next year MiMedx Group, Inc.

- sales and revenue data:

MDXG - Company Total Revenue|Projected Sales Volume MiMedx Group, Inc.|MDXG - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple MiMedx Group, Inc.

General company analysis:MDXG mimedx.com

MiMedx Group, Inc. (MDXG) operates within an isolated biotechnology cycle where stable demand for pharmaceuticals offsets macroeconomic shocks. The company's forward P/E ratio compares current market capitalization with projected earnings, reflecting investor expectations. This metric measures the degree of asset overvaluation relative to future cash flows. A declining multiple indicates that the business is undervalued. Analysis based on the forward P/E ratio helps determine the optimal entry point.

Competitors of MiMedx Group, Inc. (MDXG)